Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety

Life Sciences

Volumn 73, Issue 11, 2003, Pages 1347-1367

  Gatch, Michael B ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Anxiety; Drug discrimination; mCPP (1 (3 chlorophenyl) piperazine)

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPRAZOLAM; ANXIOLYTIC AGENT; BUSPIRONE; CALCIUM CHANNEL L TYPE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; ELTOPRAZINE; FLEXINOXAN; FLUOXETINE; IPSAPIRONE; KETANSERIN; MESULERGINE; METERGOLINE; METHYSERGIDE; MIANSERIN; PENTETRAZOLE; PIRENPERONE; PIZOTIFEN; POTASSIUM CHANNEL; RISPERIDONE; RITANSERIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRYPTOLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC SYSTEM; ANXIETY; ANXIETY DISORDER; AROUSAL; BEHAVIORAL SCIENCE; CORTICOSTERONE BLOOD LEVEL; DISCRIMINATIVE STIMULUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PROGESTERONE BLOOD LEVEL; PSYCHOMOTOR ACTIVITY; SEROTONIN UPTAKE; SHORT SURVEY; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; VALIDATION PROCESS;

ANIMALIA;

EID: 0038489422     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00422-3     Document Type: Review

References (115)

1. Abi-Saab W., Seibyl J.P., D'Souza D.C., Karper L.P., Gueorgueva R., Abi-Dargham A., Wong M.L., Rajhans S., Erdos J.P., Heninger G.R., Charney D.S., Krystal J.H. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology. 162(1):2002;55-62.
2. Appel J.B., Baker L.E., Barrett R.L., Broadbent J., Michael E.M., Riddle E.E., Van Groll B.J. Use of drug discrimination in drug abuse research. Glennon R.A., Jarbe T.U.C., Frankenheim J. Drug Discrimination: Applications to Drug Abuse Research. NIDA Research Monograph. vol. 116:1991;369-397 U.S. Government Printing Office, Washington, DC.
3. Aulakh C.S., Hill J.L., Murphy D.L. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. Journal of Pharmacology and Experimental Therapeutics. 263(2):1992;588-595.
4. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. International Journal of Neuropsychopharmacology. 4(4):2001;399-408.
5. Bagdy G., Makara G.B. Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. European Journal of Pharmacology. 275(3):1995;301-305.
6. Barnes N.M., Cheng C.H., Costall B., Ge J., Kelly M.E., Naylor R.J. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model. European Journal of Pharmacology. 218(1):1992;91-100.
7. Baumann M.H., Ayestas M.A., Dersch C.M., Rothman R.B. 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology. 24(5):2001;492-501.
8. Baumann M.H., Mash D.C., Staley J.K. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport. 6(16):1995;2150-2152.
9. Benjamin D., Lal H., Meyerson L.R. The effects of 5-HT1B characterizing agents in the mouse elevated plus-maze. Life Sciences. 47(3):1990;195-203.
10. Bersani G., Pozzi F., Marini S., Grispini A., Pasini A., Ciani N., Stutzmann J.M., Eon B., Darche F., Lucas M., Rataud J., Piot O., Blanchard J.C., Laduron P.M. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatrica Scandinavica. 83(4):1991;244-248.
11. Bilkei-Gorzó A., Gyertyán I., Lévay G. mCpp-induced anxiety in the light-dark box in rats-a new method for screening anxiolytic activity. Psychopharmacology. 136(3):1998;291-298.
12. Boja J.W., Schechter M.D. Norfenfluramine, the fenfluramine metabolite, provides stimulus control: Evidence for serotonergic mediation. Pharmacology Biochemistry and Behavior. 31(2):1988;305-311.
13. Boja J.W., Schechter M.D. Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus. European Journal of Pharmacology. 202(3):1991;347-353.
14. Bourson A., Wanner D., Wyler R., Petit N., Zwingelstein C., Rudler A., Sleight A.J. Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine. Pharmacology Biochemistry and Behavior. 53(1):1996;107-114.
15. Brandsgaard R., Barrett J.E., Rosenzweig-Lipson S. Pharmacological characterization of the discriminative stimulus effects of the potassium channel blocker 4-aminopyridine in rats. Journal of Pharmacology and Experimental Therapeutics. 295(1):2000;382-391.
16. Broocks A., Meyer T., Gleiter C.H., Hillmer-Vogel U., George A., Bartmann U., Bandelow B. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Psychopharmacology. 155(3):2001;234-241.
17. Callahan P.M., Cunningham K.A. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). European Journal of Pharmacology. 257(1-2):1994;27-38.
18. Carli M., Samanin R. Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology. 106(2):1992;228-234.
19. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology. 92(1):1987;14-24.
20. Chojnacka-Wojcik E., Klodzinska A. Involvement of 5-hydroxytryptamine2A (5-HT2A) receptors in the mediation of the discriminative stimulus properties of (+)DOI in rats. Polish Journal of Pharmacology. 49(5):1998;299-304.
21. Coplan J.D., Wolk S.I., Klein D.F. Anxiety and the serotonin 1A receptor. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1301-1310 Raven Press, New York.
22. Cunningham K.A., Appel J.B. Possible 5-hydroxytrptamine (5-HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP). Journal of Pharmacology and Experimental Therapeutics. 237(2):1986;369-377.
23. Cunningham K.A., Appel J.B. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology. 91(1):1987;67-73.
24. Cunningham K.A., Callahan P.M. Neurobehavioural pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Erinoff L., Brown R.M. Neurobiological Models for Evaluating Mechanisms Underlying Cocaine Addiction. NIDA Research Monograph. vol. 145:1994;40 Department of Health and Human Services, Government Printing Office, Washington, DC.
25. Cunningham K.A., Callahan P.M., Appel J.B. Discriminative stimulus properties of the serotonin agonist MK 212. Psychopharmacology. 90(2):1986;193-197.
26. Cussac D., Newman-Tancredi A., Quentric Y., Carpentier N., Poissonnet G., Parmentier J.G., Goldstein S., Millan M.J. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Archives of Pharmacology. 365(3):2002;242-252.
27. De Vry J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European Journal of Pharmacology. 249(3):1993;331-339.
28. Dekeyne A., Brocco M., Girardon S., Monneyron S., Veiga S., Millan M.J. Discriminative stimulus (DS) properties of the novel and potent serotonin (5-HT)2C receptor agonist, Ro 60-0175, in rats. Behavioural Pharmacology. 9(Suppl. 1):1998;S30.
29. Drukarch B., Kits K.S., Leysen J.E., Schepens E., Stoof J.C. Restricted usefulness of tetraethylammonium and 4-aminopyridine for the characterization of receptor-operated K+-channels. British Journal of Pharmacology. 98(1):1989;113-118.
30. Erzegovesi S., Martucci L., Henin M., Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology. 24(1):2001;31-36.
31. Fernandez-Guasti A., Lopez-Rubalcava C. Modification of the anxiolytic action of 5-HT1A compounds by GABA-benzodiazepine agents in rats. Pharmacology Biochemistry and Behavior. 60(1):1998;27-32.
32. Filip M., Przegalinski E. Effects of MP-3022 on the 8-OH-DPAT-induced discriminative stimulus in rats. Polish Journal of Pharmacology. 48(4):1996;397-402.
33. Fiorella D., Helsley S., Rabin R.A., Winter J.C. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazne. Psychopharmacology. 122(3):1995;237-243.
34. Fiorella D., Rabin R.A., Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology. 119(2):1995;222-230.
35. Fiorella D., Rabin R.A., Winter J.C. The interaction of clozapine with the meta-chlorophenyl piperazine (mCPP) discriminative stimulus. Life Sciences. 58(24):1996;353-358.
36. Fone K.C., Austin R.H., Topham I.A., Kennett G.A., Punhani T. Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. British Journal of Pharmacology. 123(8):1998;1707-1715.
37. Fone K.C., Shalders K., Fox Z.D., Arthur R., Marsden C.A. Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology. 123(4):1996;346-352.
38. Fone K.C., Topham I.A. Alteration in 5-hydroxytryptamine agonist-induced behaviour following a corticosterone implant in adult rats. Pharmacology, Biochemistry and Behavior. 71(4):2002;815-823.
39. Gatch M., Jung M., Wallis C., Lal H. Effects of GABA(A) compounds on mCPP drug discrimination in rats. Life Sciences. 71(22):2002;2265-2657.
40. Gatch M.B., Lal H. Animal models of the anxiogenic effects of ethanol withdrawal. Drug Development Research. 54(2):2001;95-115.
41. Gatch M.B., Wallis C.J., Lal H. Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. Alcohol. 21(1):2000;11-17.
42. George D., Benkelfat C., Rawlings R., Eckardt M., Phillips M., Nutt D., Wynne D., Murphy D., Linnoila M. Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. American Journal of Psychiatry. 154(1):1997;81-87.
43. Germine M., Goddard A., Woods S., Charney D., Heninger G. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biological Psychiatry. 32(5):1992;457-461.
44. Germine M., Goddard A.W., Sholomskas D.E., Woods S.W., Charney D.S., Heninger G.R. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Research. 54(2):1994;115-133.
45. Gibson E.L., Barnfield A.M., Curzon G. Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology. 33(3-4):1994;457-465.
46. Gleason S.D., Lucaites V.L., Shannon H.E., Nelson D.L., Leander J.D. m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behavioral Pharmacology. 12(8):2001;613-620.
47. Gleeson S., Weissman B.A., Seggel M.R., Barrett J.E. Neurochemical effects of 5-HT1 receptor ligands in pigeons. European Journal of Pharmacology. 229(2-3):1992;109-115.
48. Glennon R.A., Naiman N.A., Pierson M.E., Titeler M., Lyon R.A., Herndon J.L., Misenheimer B. Stimulus properties of arylpiperazines: NAN-190, a potential 5-HT1A serotonin antagonist. Drug Development Research. 16(2-4):1989;335-343.
49. Gommans J., Hijzen T.H., Maes R.A., Olivier B. Discriminative stimulus properties of eltoprazine. Life Sciences. 61(1):1997;11-19.
50. Gommans J., Hijzen T.H., Maes R.A., Olivier B. Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action. Psychopharmacology. 137(3):1998;292-302.
51. Gommans J., Hijzen T.H., Pattij T., Van der Gugten J., Olivier B. Discriminative stimulus properties of mCPP and alprazolam are not mediated by anxiety. Pharmacology Biochemistry and Behavior. 64(2):1999;385-387.
52. Graeff F., Netto C., Zangrossi H.J. The elevated T-maze as an experimental model of anxiety. Neuroscience and Biobehavioral Reviews. 23(2):1998;237-246.
53. Graeff F.G., Guimarães F.S., De Andrade T.G., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacology, Biochemistry and Behavior. 54(1):1996;129-141.
54. Grant K.A., Colombo G., Gatto G.J. Characterization of the ethanol-like discriminative stimulus effects of 5-HT receptor agonists as a function of ethanol training dose. Psychopharmacology. 133(2):1997;133-141.
55. Grewal S.S., Shepherd J.K., Bill D.J., Fletcher A., Dourish C.T. Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats. Psychopharmacology. 133(1):1997;29-38.
56. Griebel G., Misslin R., Pawlowski M., Vogel E. m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. Neuroreport. 2(10):1991;627-629.
57. Guimarães F., Mbaya P., Deakin J. Ritanserin facilitates anxiety in a simulated public-speaking paradigm. Journal of Psychopharmacology. 11(3):1997;225-231.
58. Hamik A., Peroutka S.J. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry. 25(5):1989;569-575.
59. Hargreaves A.C., Gunthorpe M.J., Taylor C.W., Lummis S.C. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. Molecular Pharmacology. 50(5):1996;1284-1294.
60. Helsley S., Rabin R.A., Winter J.C. Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. Progress in Neuropsychopharmacology and Biological Psychiatry. 22(2):1999;317-326.
61. Hemrick-Luecke S.K., Evans D.C. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis. Neuropharmacology. 42(2):2002;162-169.
62. Higgins G.A., Jones B.J., Oakley N.R. Effect of 5-HT1A receptor agonists in two models of anxiety after dorsal raphe injection. Psychopharmacology. 106(2):1992;261-267.
63. Hollander E., DeCaria C., Gully R., Nitescu A., Suckow R.F., Gorman J.M., Klein D.F., Liebowitz M.R. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Research. 36(1):1991;1-17.
64. Jenkins, J.A., 1998. Corticotropin-releasing factor and corticosterone modulate the anxiogenic-like effects of mCPP 60 (11), 5451B (University Microfilms No. AAI9950718).
65. Jones N., Duxon M.S., King S.M. Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: predictive validity and sensitivity to anxiogenic agents. Psychopharmacology. 161(3):2002;314-323.
66. Jung M.E., Wallis C.J., Gatch M.B., Lal H. Sex differences in anxiogenic stimuli induced by m-chlorophenylpiperazine or ethanol withdrawal. Psychopharmacology. 149(2):2000;170-175.
67. Kahn R.S., Asnis G.M., Wetzler S., van Praag H.M. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology. 96(3):1988;360-364.
68. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biological Psychiatry. 30(11):1991;1139-1166.
69. Kalus O., Kahn R.S., Wetzler S., Asnis G.M., van Praag H.M. Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks. Biological Psychiatry. 28(12):1990;1053-1057.
70. Kantor S., Anheuer Z.E., Bagdy G. High social anxiety and low aggression in Fawn-Hooded rats. Physiology and Behavior. 71(5):2000;551-557.
71. Kennett G.A., Whitton P., Shah K., Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. European Journal of Pharmacology. 164(3):1989;445-454.
72. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 36(4-5):1997;609-620.
73. Kimura K., Akai T., Nakamura K., Yamaguchi M., Nakagawa H., Oshino N. Dual activation by lisuride of central serotonin 5-HT1A and dopamine D2 receptor sites: drug discrimination and receptor binding studies. Behavioural Pharmacology. 2(2):1991;105-112.
74. Krystal J.H., Webb E., Cooney N., Kranzler H.R., Charney D.S. Specificity of ethanol like effects elicited by serotonergic and noradrenergic mechanisms. Archives of General Psychiatry. 51(11):1994;898-911.
75. Leidenheimer N.J., Schechter M.D. Inverse agonist properties of the THBC discriminative stimulus asymmetrical generalization with FG 7142. Pharmacology Biochemistry and Behavior. 38(3):1991;519-525.
76. Lopez-Rubalcava C., Saldivar A., Fernandez-Guasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacology, Biochemistry and Behavior. 43(2):1992;433-440.
77. Ma W., Pancrazio J.J., Andreadis J.D., Shaffer K.M., Stenger D.A., Li B.S., Zhang L., Barker J.L., Maric D. Ethanol blocks cytosolic Ca2+ responses triggered by activation of GABA(A) receptor/Cl-channels in cultured proliferating rat neuroepithelial cells. Neuroscience. 104(3):2001;913-922.
78. Mansbach R.S., Barrett J.E. Discriminative stimulus properties of buspirone in the pigeon. Journal of Pharmacology and Experimental Therapeutics. 240:1987;364-369.
79. Martin J.R., Ballard T.M., Higgins G.A. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacology, Biochemistry and Behavior. 71(4):2002;615-625.
80. Maurel S., Schreiber R., De Vry J. Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in the generalization of 5-HT receptor agonists to the ethanol cue in the rat. Behavioural Pharmacology. 9(4):1998;337-343.
81. McCann U.D., Eligulashvili V., Mertl M., Murphy D.L., Ricaurte G.A. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology. 147(1):1999;56-65.
82. McKenney J.D., Glennon R.A. TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacology Biochemistry and Behavior. 24(1):1986;43-47.
83. Mihara K., Yasui-Furukori N., Kondo T., Ishida M., Ono S., Ohkubo T., Osanai T., Sugawara K., Otani K., Kaneko S. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Therapeutic Drug Monitoring. 24(4):2002;563-566.
84. Miranda F., Orozco G., Velazquez-Martinez D.N. Full substitution of the discriminative cue of a 5-HT1A/1B/2C agonist with the combined administration of a 5-HT1B/2C and a 5-HT1A agonist. Behavioral Pharmacology. 13(4):2002;303-311.
85. Mora P.O., Netto C.F., Graeff F.G. Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacology, Biochemistry and Behavior. 58(4):1997;1051-1057.
86. Mos J., Van Hest A., Van Drimmelen M., Herremans A.H.J., Olivier B. The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons. European Journal of Pharmacology. 325(2-3):1997;145-153.
87. Murphy D.L., Mueller E.A., Hill J.L., Tolliver T.J., Jacobsen F.M. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology. 98(2):1989;275-282.
88. New A.S., Hazlett E.A., Buchsbaum M.S., Goodman M., Reynolds D., Mitropoulou V., Sprung L., Shaw R.B.J., Koenigsberg H., Platholi J., Silverman J., Siever L.J. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry. 59(7):2002;621-629.
89. Olivier B., Herremans A., Mos J., Van Drimmelen M., Tulp M., Van Oorschot R., Hijzen T. Discriminative stimulus properties of eltoprazine in the pigeon. Pharmacology Biochemistry and Behavior. 64(2):1999;421-427.
90. Price L.H., Goddard A.W., Barr L.C., Goodman W.K. Pharmacological challenges in anxiety disorders. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1311-1323 Raven Press, New York.
91. Rothman R.B., Baumann M.H. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacology, Biochemistry and Behavior. 71(4):2002;825-836.
92. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., Roth B.L. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 102(23):2000;2836-2841.
93. Sabbe B., Hulstijn W., Maes M., Pier M., Scharpe S., Zitman F. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers. Psychiatry Research. 105(3):2001;151-163.
94. Sanchez H., Velazquez-Martinez D.N. Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats. Journal of Psychopharmacology. 15(1):2001;29-36.
95. Schechter M.D. Tetrahydro-beta-carboline may produce its stimulus effects via a 5HT1B receptor mechanism. Pharmacology Biochemistry and Behavior. 28(1):1987;1-6.
96. Schechter M.D. Serotonergic mediation of fenfluramine discriminative stimuli in Fawn-Hooded rats. Life Sciences. 60(6):1997;83-90.
97. Sevy S., Brown S.L., Wetzler S., Kotler M., Molcho A., Plutchik R., van Praag H.M. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Research. 53(3):1994;219-229.
98. Shader R.I., Greenblatt D.J. The pharmacotherapy of acute anxiety. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1995;1341-1348 Raven Press, NY.
99. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology. 116(1):1994;56-64.
100. Silverstone P.H., Cowen P.J. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biological Psychiatry. 36(5):1994;309-316.
101. Silverstone P.H., Rue J.E., Franklin M., Hallis K., Camplin G., Laver D., Cowen P.J. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. International Clinical Psychopharmacology. 9(3):1994;173-178.
102. Stutzmann J., Eon B., Darche F., Lucas M., Rataud J., Piot O., Blanchard J., Laduron P. Are 5-HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci Letters. 128(1):1991;4-8.
103. Takahashi R.N., Berton O., Mormede P., Chaouloff F. Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze. Brazilian Journal of Medical and Biological Research. 34(5):2001;675-682.
104. Tancer M.E., Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence. 65(1):2001;97-101.
105. Vanecek S.A., Essman W.D., Taylor D.P., Woods J.H. Discriminative stimulus characteristics of BMY 14802 in the pigeon. Journal of Pharmacology and Experimental Therapeutics. 284(1):1998;1-9.
106. Wallis C.J., Lal H. A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22(3):1998;547-565.
107. Windle R.J., Shanks N., Lightman S.L., Ingram C.D. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinilogy. 138(7):1997;2829-2834.
108. Winter J.C., Rabin R.A. Discriminative stimulus properties of m-chlorophenylpiperazine. Pharmacology Biochemistry and Behavior. 45(1):1993;221-223.
109. Wolff M.C., Leander J.D. A comparison of the behavioural effect of 5-HT2A and 5-HT2C receptor agonists in the pigeon. Behavioural Pharmacology. 11(5):2000;355-364.
110. Wright I.K., Heaton M., Upton N., Marsden C.A. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology. 107(2-3):1992;405-414.
111. Ybema C.E., Slangen J.L., Olivier B., Mos J. Discriminative stimulus properties of the serotonergic compound eltoprazine. Journal of Pharmacology and Experimental Therapeutics. 260(3):1992;1045-1051.
112. Ybema C.E., Slangen J.L., Olivier B., Mos J. Dose-dependent discriminative stimulus properties of 8-OH-DPAT. Behavioural Pharmacology. 4(6):1993;610-624.
113. Ye J.H., Liu P.L., Wu W.H., McArdle J.J. Cocaine depresses GABAA current of hippocampal neurons. Brain Research. 770(1-2):1997;169-175.
114. Ye J.H., Ren J., Krnjevic K., Liu P.L., McArdle J.J. Cocaine and lidocaine have additive inhibitory effects on the GABAA current of acutely dissociated hippocampal pyramidal neurons. Brain Research. 821(1):1999;26-32.
115. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Archives of General Psychiatry. 45(2):1988;167-172.